BiotechTube
Home/Iovance Biotherapeutics/Frederick Vogt
FV

Frederick Vogt

Interim President and Chief Executive Officer

Iovance Biotherapeutics

Therapeutic Areas

OncologySolid Tumors

Iovance Biotherapeutics Pipeline

DrugIndicationPhase
Amtagvi (lifileucel)Advanced Melanoma (post-anti-PD1)Approved
LifileucelAdvanced Non-Small Cell Lung Cancer (NSCLC)Phase 2
TIL + PembrolizumabAdvanced Front-line MelanomaPhase 3

Leadership Team at Iovance Biotherapeutics

IE
Ibrahim El-Houssieny
Chief Commercial Officer
MW
Michael Weickert
Chief Technology Officer
JB
Jean-Marc Bellemin
Chief Medical Officer
RM
Ryan Maynard
Chief Financial Officer
View full Iovance Biotherapeutics profile